Stay updated on Nivolumab for ALK+ ALCL: Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for ALK+ ALCL: Clinical Trial page.

Latest updates to the Nivolumab for ALK+ ALCL: Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check13 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check20 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check27 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check49 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check63 days agoChange DetectedThe web page has been updated to include a new version of the trial description for the treatment of relapsing/refractory ALK+ Anaplastic Large Cell Lymphoma, specifically detailing the trial's structure and cohorts. The principal investigator's name has also been added.SummaryDifference49%
Stay in the know with updates to Nivolumab for ALK+ ALCL: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for ALK+ ALCL: Clinical Trial page.